Oncology Medications

FOTIVDA (tivozanib)

FOTIVDA® Available from Onco360

FOTIVDA (tivozanib) is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) and is the first and only TKI proven in rrRCC after two or more systemic therapies – including post CPI treatment.

FOTIVDA is also a differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. 1,2

FOTIVDA has been shown to significantly reduce regulatory T-cell production in pre-clinical models3 and is also being studied as a new formulation by Kyowa Kirin (KKC) in wet acute macular degeneration.

Onco360 understands the importance of monitoring renal cell carcinoma (RCC) and we are here to help. We provide ongoing and personalized support to ensure the best clinical expertise, medication adherence, and side effect management.

About FOTIVDA® 4

Recommended Dosage
The recommended dosage is 1.34 mg taken orally once daily for 21 days on treatment followed by 7 days off treatment for a 28-day cycle.

Continue treatment until disease progression or until unacceptable toxicity occurs. Take FOTIVDA with or without food.

Swallow the capsule whole with a glass of water. Do not open the capsule. If a dose is missed, the next dose should be taken at the next scheduled time. Do not take two doses at the same time.

Dosage Forms and Strength 

  • 1.34 mg: bright yellow opaque cap imprinted with “TIVZ” in dark blue ink and a bright yellow opaque body imprinted with “SD” in dark blue ink.
  • 0.89 mg: dark blue opaque cap imprinted with “TIVZ” in yellow ink and a bright yellow opaque body imprinted with “LD” in dark blue ink.

Mechanism of Action
Tivozanib is a tyrosine kinase inhibitor. In vitro cellular kinase assays demonstrated that tivozanib inhibits phosphorylation of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2 and VEGFR-3 and inhibits other kinases including c-kit and PDGFR β at clinically relevant concentrations.

In tumor xenograft models in mice and rats, tivozanib inhibited angiogenesis, vascular permeability, and tumor growth of various tumor cell types including human renal cell carcinoma.

For full prescribing information:
Click Here

Onco360 assists RCC patients with:

  • Financial assistance sourcing by our OncoAdvocate® Team for qualified patients
  • Clinical programs developed by Board-Certified Oncology Pharmacists
  • Free delivery to patient’s doorstep


Refer to the oncology experts!

Limited Distribution Oncology Medications


Oncomed Dba Onco360 or
NPI# 1679618151

VONJO™ (pacritinib) for Myelofibrosis



1 Fotivda (tivozanib) SmPC August 2017
2 Motzer RJ, Nosov D, Elsen T, et al. J Clin Oncol 2013; 31(30): 3791-9
3Pawlowski N et al. AACR 2013. Poster 3971
4FOTIVDA® prescribing information: AVEO Pharmaceuticals, Inc., Accessed 4/22